Development

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Identification of age-related protein waves in blood

New proteomic discoveries reveal a link between levels of certain proteins in human plasma and aging. The field of aging-targeting therapeutics is rapidly evolving. The...

NetraMark and Juvenescence extend collaboration

Partnership sees AI platform expanded into drug repurposing and discovery. Canadian AI technology firm NetraMark yesterday announced the extension of its NetraPharma collaboration agreement with...

Latest articles

Insurer puts down £20m to research an aging rethink

A new partnership between Legal & General and Edinburgh University aims to address the societal and economic implications of an aging society. The world is...

23andMe redundancies: DNA test market decline?

Could layoffs at 23andMe be a sign that the consumer appetite for genetic testing is declining? We expect consumer markets to transition to more...

Singapore agetech – ones to watch in 2020

Singapore thrives on its prime location at the crossroads of Asia's biggest markets, low business tax and great IT infrastructure; it is well-positioned to...

Innovating organ-on-chip to accelerate research

BIOFABICS brings custom design tools to biofabrication. While still in its infancy, organ-on-chip (OOC) technology is quickly becoming a key growth segment in the Longevity...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.